Will weight-loss drugs lead to upheaval in the sugar market?

https://www.ft.com/content/ed9a4dff-f21f-4e2b-927a-1563199e20be

Why returns have been slow to follow investment in digital health

https://www.ft.com/content/221cdff1-d6bd-46d9-a826-553b849dfe74

Small-boat crossing arrivals to UK rose 25% in 2024, data shows

https://www.ft.com/content/8f9d45c4-1f4d-4260-af63-033c37ead1bf

Vanguard strikes deal with FDIC over huge holdings in US banks

https://www.ft.com/content/06f8b82b-1eac-4744-a01c-35c5598980c0

Global corporate borrowing climbs to record $8tn in 2024

https://www.ft.com/content/3bb5df0d-f5d6-4360-9a6a-d27dabb3e5a2

Tech pullback drags Wall Street stocks lower

https://www.ft.com/content/5e7e124f-d481-428d-81a1-117c1a734a6f

Eli Lilly given US approval to treat sleep disorder with weight-loss drug

https://www.ft.com/content/d7fb5cf1-e6d2-4aa9-8c42-8faf67388069

Letter: Uplifting account of a wrongful incarceration

https://www.ft.com/content/49e53bd1-ef34-4f27-8e9b-6daff1e5e1a2

Letter: Fentanyl deaths slowdown is not result of innovation

https://www.ft.com/content/34b468d1-452d-4c51-9997-148eced64178

South Korea’s central bank chief warns over Gangnam-style housing boom

https://www.ft.com/content/e95a7394-af55-410a-b111-28b1076fcec4